← Leaderboards
Grace L Guo
Va New Jersey Health Care System
$5,665,608
Attributed
$5,665,608
Total exposure
17
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $667.9K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,665,608 · 16
VA$0 · 1
By mechanism
R01$3,901,918 · 3
P20$1,009,015 · 11
R21$426,250 · 1
R56$328,425 · 1
I01$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Liver”
- David Heimbrook · Leidos Biomedical Research, Inc.$183,557,534
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Richard Douglas Moore · Johns Hopkins University$59,048,354
- Paul M. Ridker · Brigham And Women'S Hospital$55,416,022
- Michael S. Saag · University Of Alabama At Birmingham$50,288,385
- Mark A Kay · Stanford University$49,905,067
Research focus
LiverPreventReceptorNuclear ReceptorsMouse ModelPathway InteractionsIntestinesHomeostasisBile Acid Biosynthesis PathwayFibroblast Growth FactorLiver DiseasesMolecularBile AcidsFutureLigandsSignal TransductionKnockout MiceMediatingGene ExpressionInnovationBaseMedicalProteinsTransgenic Mice
Grant awards (37)
Role of Intestinal Bile Acid Signaling in Liver Diseases$0
I01 · FY2025 · VA · contact PI
Role of Intestinal Bile Acid Signaling in Liver Diseases$0
I01 · FY2024 · VA · contact PI
Gut-liver crosstalk by FGF15/19 in regulating xenobiotic nuclear receptor activation$314,000
R01 · FY2023 · GM · contact PI
Role of Intestinal Bile Acid Signaling in Liver Diseases$0
I01 · FY2023 · VA · contact PI
Gut-liver crosstalk by FGF15/19 in regulating xenobiotic nuclear receptor activation$314,000
R01 · FY2022 · GM · contact PI
Gut-liver crosstalk by FGF15/19 in regulating xenobiotic nuclear receptor activation$70,031
R01 · FY2022 · GM · contact PI
Role of Intestinal Bile Acid Signaling in Liver Diseases$0
I01 · FY2022 · VA · contact PI
Gut-liver crosstalk by FGF15/19 in regulating xenobiotic nuclear receptor activation$397,624
R01 · FY2021 · GM · contact PI
Gut-liver crosstalk by FGF15/19 in regulating xenobiotic nuclear receptor activation$13,929
R01 · FY2021 · GM · contact PI
Gut-liver crosstalk by FGF15/19 in regulating xenobiotic nuclear receptor activation$312,000
R01 · FY2020 · GM · contact PI
Role of FGF15 in liver regeneration$0
I01 · FY2020 · VA · contact PI
Differential roles of FXR and FGF15 in liver fibrosis development$193,750
R21 · FY2019 · ES · contact PI
Role of FGF15 in liver regeneration$0
I01 · FY2019 · VA · contact PI
Differential roles of FXR and FGF15 in liver fibrosis development$232,500
R21 · FY2018 · ES · contact PI
Role of FGF15 in liver regeneration$0
I01 · FY2018 · VA · contact PI
Gut bile acids, Fxr, & Fgf15 in total parenteral nutrition-associated cholestasis$277,680
R01 · FY2016 · GM · contact PI
Gut bile acids, Fxr, & Fgf15 in total parenteral nutrition-associated cholestasis$277,680
R01 · FY2015 · GM · contact PI
Gut bile acids, Fxr, & Fgf15 in total parenteral nutrition-associated cholestasis$282,435
R01 · FY2014 · GM · contact PI
Gut bile acids, Fxr, & Fgf15 in total parenteral nutrition-associated cholestasis$300,425
R01 · FY2013 · GM · contact PI
FXR, nuclear receptors, and transcriptional regulation of liver homeostasis$328,425
R56 · FY2011 · DK · contact PI
Tissue specific mechanism of FXR in suppressing bile-acid synthesis$264,919
R01 · FY2011 · DK · contact PI
Tissue specific mechanism of FXR in suppressing bile-acid synthesis$41,239
R01 · FY2011 · DK · contact PI
COBRE: U OF KANSAS MEDICAL CTR: NULL-MOUSE CORE$33,331
P20 · FY2011 · RR · contact PI
Tissue specific mechanism of FXR in suppressing bile-acid synthesis$311,456
R01 · FY2010 · DK · contact PI
Tissue specific mechanism of FXR in suppressing bile-acid synthesis$99,750
R01 · FY2010 · DK · contact PI
COBRE: U OF KANSAS MEDICAL CTR: NULL-MOUSE CORE$31,240
P20 · FY2010 · RR · contact PI
Tissue specific mechanism of FXR in suppressing bile-acid synthesis$312,375
R01 · FY2009 · DK · contact PI
COBRE: U OF KANSAS MEDICAL CTR: CORE C: NULL-MOUSE CORE$39,226
P20 · FY2009 · RR · contact PI
Tissue specific mechanism of FXR in suppressing bile-acid synthesis$312,375
R01 · FY2008 · DK · contact PI
FXR ALTERS HEPATIC LIPID METABOLISM & DECREASES FATTY LIVER DEVELOPMENT$190,723
P20 · FY2008 · RR · contact PI
COBRE: U OF KANSAS MEDICAL CTR: CORE C: NULL-MOUSE CORE$43,911
P20 · FY2008 · RR · contact PI
PROJ 2: FXR ALTERS HEPATIC LIPID METABOLISM & DECREASES FATTY LIVER DEVELOPMENT$220,059
P20 · FY2007 · RR · contact PI
COBRE: U OF KANSAS MEDICAL CTR: CORE C: NULL-MOUSE CORE$85,191
P20 · FY2007 · RR · contact PI
FARNESOID X RECEPTOR ATTENUATES COLON CARCINOGENESIS$14,503
P20 · FY2007 · RR · contact PI
PROJ 2: FXR ALTERS HEPATIC LIPID METABOLISM & DECREASES FATTY LIVER DEVELOPMENT$218,887
P20 · FY2006 · RR · contact PI
COBRE: U OF KANSAS MEDICAL CTR: CORE C: NULL-MOUSE CORE$96,793
P20 · FY2006 · RR · contact PI
FARNESOID X RECEPTOR ATTENUATES COLON CARCINOGENESIS$35,151
P20 · FY2006 · RR · contact PI